bronchodilator-containing inhalers and placebo inhalers in a clinical trial setting. We are puzzled to be criticised for reference to older literature on electronic adherence devices⁹ and sought only to point out that electronic monitoring of relevant dry powder inhalers had long been available to explore the hypothesis that timing of medication use was somehow important to the mechanism of action of SMART. Reddel and Yan have mentioned numerous 'errors' in our review but provided only examples of our emphasis on control and compliance assessments hitherto overlooked in SMART research; we look forward to correcting any errors of fact they detect and report to us.

Finally, we wish to clarify further our thoughts concerning the measurement of inflammatory indices in SMART-treated patients. We agree with Peters and Jenkins that control outcomes were neither superior nor inferior for SMART compared with fixed dose treatment in the study by Pavord and colleagues,¹⁰ and would add that the study was neither adequately powered nor designed to examine this outcome. With respect to eosinophil counts being 'in the range of control', we are not sure that there is sufficient long-term literature using sputum eosinophil counts to declare with confidence that a particular level of airway eosinophilia is safe and acceptable in asthma. However, if one accepts that levels of <3% are tolerable, we note that it was only the mean sputum eosinophil count that was within this limit for SMART-treated patients and the rise in sputum eosinophils seen with SMART therapy probably increased the proportion of SMART-treated patients above the 'acceptable' limit. We find this increase as well as the doubling of biopsy eosinophil counts concerning.

**Kenneth R Chapman,¹ Neil C Barnes,²
Andrew P Greening,³ Paul W Jones,⁴
Soren Pedersen⁵**

¹Asthma and Airway Centre, University Health Network, University of Toronto, Toronto, Canada; ²Department of Respiratory Medicine, London Chest Hospital, London, UK; ³Department of Pulmonary Disease, Respiratory Unit, Western General Hospital, Edinburgh, UK; ⁴Division of Clinical Science, St George's, University of London, London, UK; ⁵Pediatric Research Unit, Kolding Hospital, Kolding, Denmark

Competing interests In the past 3 years KRC has received compensation for consulting with AstraZeneca, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Merck Frosst, Novartis, Nycomed, Pfizer, Roche, Schering Plough and Telacris; has undertaken research funded by AstraZeneca, Boehringer-Ingelheim, CSL Behring, Forest Labs, GlaxoSmithKline, Novartis, Parangenix, Roche and Talecris; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, MerckFrosst, Novartis, Nycomed, Pfizer and Talecris. NCB has lectured for or received consulting fees from GlaxoSmithKline, AstraZeneca, Altana, Merck Generics, Chiesi and TEVA and has received grant support from GlaxoSmithKline and AstraZeneca. APG has received lecture fees from AstraZeneca and

GlaxoSmithKline in the past year. PWJ has received consultancy fees from GlaxoSmithKline, AstraZeneca, Almirall, Boehringer Ingelheim and Spiration; has received lecture fees from GlaxoSmithKline; and his institution will from his time as a consultant to Novartis. Within the past 3 years, SP has received compensation for consulting with Nycomed, GlaxoSmithKline, Neolab and AstraZeneca and has given lectures sponsored by Nycomed and GlaxoSmithKline. This manuscript was conceived, researched and written by the authors without assistance from employees of the pharmaceutical industry or their agents. No professional writers participated in the preparation of the manuscript.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 13 September 2010

Published Online First 19 November 2010

Thorax 2011;**66**:87–88. doi:10.1136/thx.2010.151167

REFERENCES

1. **Peters MJ**, Jenkins CR. Critical appraisal of Symbicort maintenance and reliever treatment misrepresents the clinical evidence. *Thorax* 2011;**66**:86–7.
2. **Chapman KR**, Barnes NC, Greening AP, *et al*. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2010;**65**:747–52.
3. **Bateman ED**, Reddel HK, Eriksson G, *et al*. Overall asthma control: the relationship between current control and future risk. *J Allergy Clin Immunol* 2010;**125**:600–8.
4. **Reddel H**, Yan KY. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2011;**66**:86–7.
5. **Cates CJ**, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2009;(1):CD007085.
6. **Bowler S**, Serisier D. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2011;**66**:87.
7. **Rabe KF**, Pizzichini E, Stallberg B, *et al*. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. *Chest* 2006;**129**:246–56.
8. **Kuna P**, Peters MJ, Manjra AI, *et al*. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. *Int J Clin Pract* 2007;**61**:725–36.
9. **Bosley CM**, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? *Eur Respir J* 1994;**7**:504–9.
10. **Pavord ID**, Jeffery PK, Qiu Y, *et al*. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. *J Allergy Clin Immunol* 2009;**123**:1083–9.

Editors' response

The review article by Chapman *et al*¹ has provoked a vigorous correspondence,^{2–5} amongst other things calling on *Thorax* to 'respond appropriately' and even withdraw the manuscript. We inherited the manuscript from our predecessors and played no part in its commissioning or review. However, we are quite clear that the appropriate response is not to withdraw the manuscript, but rather to allow a vigorous debate in the correspon-

dence columns. Withdrawal of the manuscript would only be the response if there was clear evidence of duplicate publication, data fabrication or some other piece of flagrant dishonesty, which is not the case. In this manuscript, the final conclusion is that we do not have enough evidence to determine whether a reactive asthma strategy such as SMART is preferable to a chronic suppressive study. This is undoubtedly true. Perhaps we will ultimately conclude that this question cannot be answered definitively and we should accept that there is more than one effective way to approach the goals of asthma control and risk reduction. Many would argue that this is a good thing as our patients have different expectations and concerns about chronic drug treatment for asthma.

We welcome debate about the article, and we will consider other relevant letters and articles if submitted, inviting the authors to respond. We are grateful to the reviewers, who do a fine job, but it is the authors who are responsible for the manuscript. Above all, we need to work together to design robust clinical trials with appropriate and relevant end points to answer the great questions about asthma treatment. Sound and fury, no matter what the source, is no substitute for primary data.

Andrew Bush,¹ Ian Pavord²

¹Department of Paediatric Respiratory Medicine, Imperial College and Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; ²Department of Respiratory Medicine, Thoracic Surgery and Allergy, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK

Correspondence to Andrew Bush, Department of Paediatric Respiratory Medicine, Imperial College and Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; A.Bush@rbht.nhs.uk

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 4 October 2010

Published Online First 19 November 2010

Thorax 2011;**66**:88. doi:10.1136/thx.2010.152744

REFERENCES

1. **Chapman KR**, Barnes NC, Greening AP, *et al*. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2010;**65**:747–52.
2. **Reddel HK**, Yan KY. Response to 'Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal'. *Thorax* 2011;**66**:86–7.
3. **Peters MJ**, Jenkins CR. Response to 'Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal'. *Thorax* 2011;**66**:86–7.
4. **Bowler S**, Serisier D. Response to 'Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal'. *Thorax* 2011;**66**:87.
5. **Chapman KR**, Barnes NC, Greening AP, *et al*. Response to 2–4. *Thorax* 2011;**66**:87–8.